Cargando…

Pathogenic variants in the healthy elderly: unique ethical and practical challenges

Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacaze, Paul, Ryan, Joanne, Woods, Robyn, Winship, Ingrid, McNeil, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629947/
https://www.ncbi.nlm.nih.gov/pubmed/28341755
http://dx.doi.org/10.1136/medethics-2016-103967
_version_ 1783269152571523072
author Lacaze, Paul
Ryan, Joanne
Woods, Robyn
Winship, Ingrid
McNeil, John
author_facet Lacaze, Paul
Ryan, Joanne
Woods, Robyn
Winship, Ingrid
McNeil, John
author_sort Lacaze, Paul
collection PubMed
description Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should be managed differently from standard practices adapted for younger populations has not yet been defined. In this article, we provide an overview of ethical and practical challenges in preparing for a genetic study of over 14 000 healthy Australians aged 70 years or older enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank. At the time of consent, all participants in this study were free of life-threatening illness, cardiovascular disease or cognitive impairment. ASPREE is thus a cohort of healthy elderly individuals with seemingly minimal burden of genetic disease recruited without ascertainment bias. The cohort presents a unique opportunity to address the penetrance of known pathogenic variants in a population without disease symptoms; however, it also raises a number of ethical concerns regarding the interpretation and disclosure of variants with known clinical actionability. Some of the challenges include (a) how to manage the interpretation, disclosure and actioning of pathogenic variants found in otherwise healthy elderly adults without disease symptoms, (b) whether or not to disclose findings for the benefit of family members rather than elderly consented donors themselves, (c) how to manage the return of genetic findings to the elderly individuals who are now in severe cognitive decline or terminal illness, (d) how to ensure quality of information and clinical service upon disclosure of results to this demographic and (e) how to prepare for the insurance implications of disclosing genetic information under Australian law. We discuss these and other dilemmas and propose a defensible plan of management. TRIAL REGISTRATION NUMBER: ISRCTN83772183
format Online
Article
Text
id pubmed-5629947
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56299472017-10-11 Pathogenic variants in the healthy elderly: unique ethical and practical challenges Lacaze, Paul Ryan, Joanne Woods, Robyn Winship, Ingrid McNeil, John J Med Ethics Genetics Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should be managed differently from standard practices adapted for younger populations has not yet been defined. In this article, we provide an overview of ethical and practical challenges in preparing for a genetic study of over 14 000 healthy Australians aged 70 years or older enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank. At the time of consent, all participants in this study were free of life-threatening illness, cardiovascular disease or cognitive impairment. ASPREE is thus a cohort of healthy elderly individuals with seemingly minimal burden of genetic disease recruited without ascertainment bias. The cohort presents a unique opportunity to address the penetrance of known pathogenic variants in a population without disease symptoms; however, it also raises a number of ethical concerns regarding the interpretation and disclosure of variants with known clinical actionability. Some of the challenges include (a) how to manage the interpretation, disclosure and actioning of pathogenic variants found in otherwise healthy elderly adults without disease symptoms, (b) whether or not to disclose findings for the benefit of family members rather than elderly consented donors themselves, (c) how to manage the return of genetic findings to the elderly individuals who are now in severe cognitive decline or terminal illness, (d) how to ensure quality of information and clinical service upon disclosure of results to this demographic and (e) how to prepare for the insurance implications of disclosing genetic information under Australian law. We discuss these and other dilemmas and propose a defensible plan of management. TRIAL REGISTRATION NUMBER: ISRCTN83772183 BMJ Publishing Group 2017-10 2017-03-24 /pmc/articles/PMC5629947/ /pubmed/28341755 http://dx.doi.org/10.1136/medethics-2016-103967 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Genetics
Lacaze, Paul
Ryan, Joanne
Woods, Robyn
Winship, Ingrid
McNeil, John
Pathogenic variants in the healthy elderly: unique ethical and practical challenges
title Pathogenic variants in the healthy elderly: unique ethical and practical challenges
title_full Pathogenic variants in the healthy elderly: unique ethical and practical challenges
title_fullStr Pathogenic variants in the healthy elderly: unique ethical and practical challenges
title_full_unstemmed Pathogenic variants in the healthy elderly: unique ethical and practical challenges
title_short Pathogenic variants in the healthy elderly: unique ethical and practical challenges
title_sort pathogenic variants in the healthy elderly: unique ethical and practical challenges
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629947/
https://www.ncbi.nlm.nih.gov/pubmed/28341755
http://dx.doi.org/10.1136/medethics-2016-103967
work_keys_str_mv AT lacazepaul pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges
AT ryanjoanne pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges
AT woodsrobyn pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges
AT winshipingrid pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges
AT mcneiljohn pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges